Healthcare IT & regulatory technology · Pharma labeling and promotional compliance
Entvin
An AI agent platform built to speed up FDA and EMA labeling and promotional material review for pharmaceutical regulatory, medical affairs and commercial teams. Out of Y Combinator’s Summer 2022 batch, it raised its first disclosed outside funding, $500,000 from Y Combinator, in March 2025.
Reading labels for a living
A regulatory affairs team at a large pharmaceutical company spends its week comparing drug labels. When the FDA updates a competitor’s label, someone has to notice, read the change, and work out what it means for pricing, sales talking points, or the company’s own submissions. When a promotional flyer goes out, someone has to check every claim against the FDA-approved label and the relevant 21 CFR rules before it reaches a doctor’s inbox. Entvin was built to do that watching and checking with software instead of a person paging through PDFs.
The company describes itself on its own site in blunt terms: “Entvin AI is an intelligent agent platform which streamline FDA compliance for regulatory, medical affairs and commercial teams.” Two named products carry that work. Labeling AI tracks label updates across the FDA, the European Medicines Agency and Australia’s TGA, and compares old and new label versions side by side. Ads Promo AI reviews promotional materials against FDA guidelines and 21 CFR regulations and helps maintain a library of approved marketing claims.
The problem it names, and the narrower one it solves
In pitching reporters on its March 2025 funding, Entvin named a large target. The FDA drug approval process, the company told Business Standard and roughly a dozen other outlets that ran versions of the same release, “often takes years and costs millions,” and “any inefficiency can significantly impact a company’s bottom line and delay potentially life-saving treatments from reaching patients.” Its own website names a narrower problem, at the post-approval labeling and promotional stage: “Regulatory teams today spend weeks manually tracking FDA and EMA updates, analyzing drug databases, and preparing reports.”
That narrower problem, tracking label changes and vetting promotional copy, is real and well documented in regulatory affairs circles, and it is the one Entvin’s actual feature list addresses: label version comparison, an AI label drafter, competitor label search, and automated review of promotional material against FDA rules. Whether the platform also touches the earlier, harder-to-automate parts of the approval process, such as clinical submissions, is not established by anything found in this research; the company’s YC listing speaks broadly of agents “to support regulatory teams,” while its shipped product is specifically about labels and ads.
Two IIT Bombay classmates, and a third name in the press
Y Combinator’s company page lists two active founders. Sanskar Jain, the CEO, has a mechanical engineering degree from IIT Bombay and previously led growth and strategy at andMe, a direct-to-consumer brand acquired by GlobalBees, after a stint as an analyst in Alvarez & Marsal’s strategy and commercial due diligence practice in India. Hemant Phalak, the chief product officer, has a B.Tech in material sciences from IIT Bombay and was a founding team member at the cross-border fintech Zolve, after working as an associate at PwC India’s technology consulting practice.
Press coverage of the March 2025 funding names a third co-founder, Rishabh Arya, as chief technology officer, and quotes him describing the platform’s architecture. Arya does not appear among Y Combinator’s current Active Founders for Entvin, and he is not listed as a director of Entvin Labs Private Limited, the company’s India subsidiary, whose only two directors on record are Jain and Phalak. Nothing found here explains the gap; it may mean Arya left an operating role, or simply that Y Combinator’s bios were not updated.
From a Bengaluru filing to a first check
Entvin’s India entity, Entvin Labs Private Limited, was incorporated in Bengaluru on August 19, 2022, the same year Y Combinator accepted the company into its Summer 2022 batch. For roughly two and a half years afterward, no outside funding round was disclosed, while the company built the Labeling AI and Ads Promo AI products and, per its later press statements, worked with unnamed “enterprise pilot customers.”
On March 28, 2025, Business Standard reported that Entvin had raised “Entvin AI raises Rs 5 crore in first funding round from Y Combinator,” a figure the company and nearly a dozen outlets converted to $500,000 in the days that followed. Several outlets described the moment as a launch out of beta.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| India subsidiary | Entvin Labs Private Limited, CIN U72900KA2022FTC165078, incorporated Aug 19, 2022 in Bengaluru, classified by India’s Ministry of Corporate Affairs as a subsidiary of a company incorporated outside India. Authorized capital Rs 10,00,000, paid-up capital Rs 1,00,000. Directors on record: Sanskar Jain and Hemant Laxman Phalak. | Public record |
| SEC filings | No Form D or other filing found under “Entvin” in a SEC EDGAR company search run Sep 25, 2026. | Not found |
| FDA, NIH, NSF, trials, PubMed | No FDA 510(k) or PMA record, no registered clinical trial, no NIH or NSF award, and no PubMed listing found for the company. | Not found |
| First funding | $500,000 reported from Y Combinator, announced Mar 28, 2025 and described by the company as its first round of funding. | Independent reporting |
| Third co-founder | Rishabh Arya is named chief technology officer and quoted in March and April 2025 press coverage, but does not appear among Y Combinator’s Active Founders and is not a director of the India subsidiary. | Differs from YC listing |
| Security and compliance certifications | The company’s website and its executives, quoted in press coverage, describe the platform as enterprise-grade and meeting SOC 2, ISO 27001, HIPAA and GDPR standards. No certificate, auditor, or third-party attestation was found. | Company-stated |
| Customers | The website states the platform is “Trusted by R&D and pharma professionals from world’s leading organisations” and carries testimonials attributed only to job titles, such as “Director Global Labeling, Large Biotech.” No customer company is named. | Company-stated |
Read plainly: Entvin is a three-year-old software company with one disclosed funding event, an active India subsidiary, and a product description that has narrowed over time, from broad language about the FDA approval process to a specific pair of tools for label tracking and promotional review. The claims about enterprise-grade security and pilot customers are the company’s own; nothing external found in this research confirms them.
What to watch
- Whether Entvin ever files a Form D or another SEC record, which would put a regulator-sourced number on any round raised since the $500,000 from Y Combinator.
- A named customer. Every reference to pilot or paying users found in this research describes them only by size or job title.
- Rishabh Arya’s status at the company, given the gap between the March 2025 press coverage naming him CTO and his absence from Y Combinator’s current founder listing.
- Independent confirmation of the SOC 2, ISO 27001, HIPAA and GDPR claims made on the company’s site.
In their words
“Regulatory professionals spend countless hours on documentation, compliance checks, and staying updated with constantly evolving FDA guidelines. Our artificial intelligence agents streamline these workflows, allowing teams to focus on strategic priorities rather than administrative burdens.”
Sanskar Jain, co-founder and CEO, Business Standard, Mar 28, 2025 · Company statement
“At Entvin, our AI agents seamlessly integrate into existing workflows to enhance efficiency and accelerate decision-making. Our platform doesn’t just organize information - it actively identifies compliance gaps, automates repetitive documentation tasks, and provides regulatory teams with actionable insights in real time.”
Hemant Phalak, co-founder and CPO, Indian Startup News, Apr 2, 2025 · Company statement
“We’ve developed an artificial intelligence system that deeply understands the complex language of FDA regulations and can process massive volumes of regulatory documentation. Our architecture is enterprise-grade, designed to meet the highest compliance standards required by pharmaceutical companies like SOC 2 and ISO 2700.”
Rishabh Arya, co-founder and CTO, Business Standard, Mar 28, 2025 · Company statement
“Entvin AI is an intelligent agent platform which streamline FDA compliance for regulatory, medical affairs and commercial teams.”
Entvin website, accessed via archive Jul 2, 2025 · Company website
“Entvin Ads Promo AI has revolutionized how we review promotional materials. Its AI-powered compliance checks against FDA guidelines and 21 CFR regulations allow us to identify risks instantly, saving us countless hours of manual review.”
Unnamed customer, titled Director Advertising and Promotions, Large Pharma, Entvin website · Website testimonial
“Entvin’s AI-powered evidence search is a game-changer. Unlike traditional keyword searches that often miss context, the AI intelligently understands regulatory intent and surfaces the most relevant FDA letters, 21 CFR rules, and past decisions.”
Unnamed customer, titled Senior Director Promotional Regulatory, Mid-Size Pharma, Entvin website · Website testimonial
Related companies
Sources
- Public recordEntvin Labs Private Limited, CIN U72900KA2022FTC165078, MCA registry data
- Not foundSEC EDGAR company search, “Entvin”
- YC dataEntvin company page
- CompanyEntvin (YC S22) company page
- CompanyEntvin homepage
- CompanyEntvin blog index
- CompanyIntroducing Ask AI: Revolutionizing Regulatory Document Review
- CompanyLabel Updates: Your New Competitive Advantage in Pharma
- IndependentEntvin AI raises Rs 5 crore in first funding round from Y Combinator
- IndependentEntvin AI raises $500K from Y Combinator
- IndependentEntvin AI raises $500K in Y Combinator funding to streamline FDA drug approval process
- IndependentPharma Breakthrough: Entvin AI Lands $500K for FDA Boost
- IndependentIIT Bombay graduates-founded startup Entvin AI raises $500,000 from Y Combinator
- IndependentIIT Bombay Graduates’ Startup Entvin AI Secures USD 500,000 from Y Combinator
- IndependentEvenflow, Wendor, Entvin AI, The Bear House, InnerGize raise funding
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
